Navigation Links
A “Fail Fast” Strategy for Lead Optimization Pharmacology and Toxicology, New Xtalks Life Sciences Webinar
Date:3/21/2013

Toronto, Canada (PRWEB) March 21, 2013

Successful drug development is increasingly dependent on a robust “fail fast” strategy that includes incorporation of safety/toxicology endpoints into lead optimization pharmacology studies. This early marriage of pharmacology and toxicology will provide insight into the margin of safety that is critical for advancing the molecule, the design of the good laboratory practice studies and the clinical plan.

This webinar will focus on lead optimization pharmacology and toxicology and a fail fast strategy that many companies are using. The advantages and disadvantages of incorporating safety and toxicology endpoints in pharmacology studies will be discussed along with case studies demonstrating their potential value.

For more information about this event or to register, visit: http://xtks.in/xto583-event.

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year, thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about, Xtalks visit http://xtalks.com/ContactUs.ashx.

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/3/prweb10548848.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1

Related biology technology :

1. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
2. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
3. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
4. SPO Updates Shareholders on 2012 Corporate Strategy
5. Meaningful Use Stage Two: The Advisory Board Company Helps Hospitals Set Strategy
6. Synteract Unveils New Branding at DIA 2012 to Support Enhanced Commercial Strategy
7. New gene therapy strategy boosts levels of deficient protein in Friedreichs ataxia
8. Womens Health Expert GC-Rise Ties up with Georgetown MBA Team to Tap M&A Potential and Growth Strategy
9. ASAE, TMG Custom Media Collaborate to Launch New Print-Plus-Digital Strategy for Associations Now Magazine
10. Elsevier / MEDai Names Dr. Peter Edelstein as Chief Medical Officer and Dr. Gerald Osband as Director of Product Strategy
11. Creabilis Receives Prestigious Technology Strategy Board Biomedical Catalyst Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... New York, and New York, New York (PRWEB) , ... ... ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it ... and develop new vaccines and immunotherapies for infectious diseases and cancer. ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark Research, a fully-integrated ... of two long-standing principal investigators (PI) to the roles of Chief Medical Officer, ... , Dr. Laurence Chu, a Benchmark Research PI in the Austin office, will ...
(Date:2/10/2016)... CA (PRWEB) , ... February 10, 2016 , ... ... Multiplex Testing (PROMPT), a research registry built on the secure online PatientCrossroads platform, ... 2014. More than 1,600 participants have joined the PROMPT study, which seeks to ...
(Date:2/10/2016)... BC (PRWEB) , ... February 09, 2016 , ... ... design services and current winner of the Highest Overall Customer Rating Award ... in all of its business units across the USA, Canada, Mexico and China. ...
Breaking Biology Technology:
(Date:2/1/2016)... 1, 2016 Rising sales of ... global touchfree intuitive gesture control market size ... sales of consumer electronics coupled with new technological advancements ... size through 2020   --> ... new technological advancements to drive global touchfree intuitive gesture ...
(Date:1/28/2016)... 2016 Synaptics (NASDAQ: SYNA ), a leading developer ... quarter ended December 31, 2015. --> ... 2016 increased 2 percent compared to the comparable quarter last year ... 2016 was $35.0 million, or $0.93 per diluted share. ... the first quarter of fiscal 2016 grew 9 percent over the ...
(Date:1/25/2016)... SEATTLE , Jan. 25, 2016  Glencoe Software, ... biotech, pharma and publication industries, will provide the data ... Phenotypic Screening Centre (NPSC). ... Phenotypic analysis ... even whole organisms, allowing comparisons between states such as ...
Breaking Biology News(10 mins):